Top Reasons CAR T-Cell Therapies Not Offered by HCPs in Italy1,a,b

In Italy, top reasons for not offering CAR T-cell therapies included logistical challenges and delay in starting treatment

aTop reason defined as any reason that was given by more than 25% of HCPs during the survey. bQuestions about BsAb therapy were not asked to HCPs in Italy.

BsAb, bispecific antibody; CAR, chimeric antigen receptor; HCP, health care professional.

Reference

  1. Zamagni E, Kevin B, Cormier N, et al. Differences across countries in healthcare provider confidence with CAR-T and bispecific antibody therapies for relapsed/refractory multiple myeloma. Presented at: EHA 2025 Congress; June 12-15, 2025; Milan, Italy. Poster PS1751.